Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31611960 | 1.00 | KMT2A (0.43) | KMT2APKMALDH1A1HTTNAMPT | |
| SCHEMBL21617111 | 0.86 | PKM (0.38) | PKMLMNANR1H4 | |
| SCHEMBL28618751 | 0.82 | KMT2A (0.39) | KMT2AALDH1A1HTTNAMPTMEN1 | |
| SCHEMBL22899612 | 0.81 | SMN1; SMN2 (0.38) | KMT2APKMALDH1A1HTTNAMPT | |
| SCHEMBL29486220 | 0.81 | SMN1; SMN2 (0.38) | KMT2APKMALDH1A1HTTNAMPT | |
| SCHEMBL21616999 | 0.80 | SMN1; SMN2 (0.36) | KMT2APKMALDH1A1HTTNAMPT | |
| SCHEMBL31504370 | 0.80 | CNR2 (0.42) | KMT2AALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL21617159 | 0.80 | CNR2 (0.42) | KMT2AALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL30511547 | 0.80 | SMN1; SMN2 (0.36) | KMT2APKMALDH1A1HTTNAMPT | |
| SCHEMBL29486146 | 0.78 | SMN1; SMN2 (0.41) | KMT2AALDH1A1MEN1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-09-30 | — | — | US | disclosed |
| EP-3820848-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112703183-A | aryl-N-aryl derivatives for the treatment of RNA viral infections | ABIVAX公司 | 2021-04-23 | — | — | CN | disclosed |
| WO-2020011811-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011811-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | HAVCR2, CBR3, C1R | KMT2A 2616/4885PKM 3365/4885ALDH1A1 2537/4885 |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | HAVCR2, CBR3, C1R | KMT2A 2616/4885PKM 3365/4885ALDH1A1 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.